

F. Nicholas Franano, MD
President and CEO



F. Nicholas Franano, MD, is a physician, scientist, inventor and entrepreneur. He is President and CEO of Flow Forward Medical, a company developing the Arteriovenous Fistula Eligibility (AFE) System™, a medical device designed to rapidly establish high-quality vascular access sites for hemodialysis patients. Dr. Franano also serves as President and CEO of Metactive Medical, a company developing novel, endovascular medical devices for the treatment of peripheral vascular and neurovascular diseases.

Previously, Dr. Franano served as founder and CEO of Novita Therapeutics, LLC, a cardiovascular medical device incubator, where he raised \$10 million in capital and successfully spun out Flow Forward and Metactive. Prior to this, Dr. Franano founded Proteon Therapeutics and served as its CEO and CSO, leading the development of Proteon's lead drug candidate, PRT-201, and helping to raise more than \$89 million in capital. He continues to serve as a member of the Proteon Board of Directors. Before founding Proteon, he maintained an active clinical practice in interventional radiology, performing a wide range of vascular and non-vascular procedures.

Dr. Franano received an MD and an MS degree in biomedical research from Washington University in St. Louis. He completed a residency in diagnostic radiology and a fellowship in interventional radiology at Johns Hopkins Hospital. He has received numerous research awards, grants and fellowships, and has published many abstracts and articles in peer-reviewed journals. Dr. Franano holds 11 patents and more than 30 pending patent applications. In 2009, Dr. Franano was named a "Technology Pioneer" by the World Economic Forum and an Ernst & Young "Entrepreneur of the Year" for the Central Midwest. Dr. Franano also serves on the Board of Directors of the Greater Kansas City Chamber of Commerce, the Biological Sciences Advisory Board at the University of Kansas, the Advisory Board of the Enterprise Investment Program at the University of Missouri, and the Entrepreneurship Council at Washington University in St. Louis.

William P. Whitaker, Esq.
Vice President, Finance and General Counsel



William P. Whitaker is co-founder, Vice President of Finance and General Counsel at Flow Forward Medical, and also serves in the same roles at Metactive Medical, a company developing novel, endovascular medical devices for the treatment of peripheral vascular and neurovascular diseases.

Previously, Whitaker co-founded Novita Therapeutics, LLC, and Proteon Therapeutics, where he also served as Vice President and General Counsel. While at Novita Therapeutics, he helped raise \$10 million in capital and led the spinouts of Flow Forward and Metactive. During his time at Proteon, Whitaker helped raise more than \$89 million in capital to advance the company's lead drug product, PRT-201, from conception to the completion of a successful Phase 2b clinical trial. Prior to founding Proteon and Novita, Whitaker held partnerships in two law firms before forming his own law practice. During this time, he worked as a lawyer in areas as diverse as corporate law and financing, estate planning, municipal bond financing, real estate development, litigation and

transportation. Additionally, he has served on the Boards of Directors for the Heart of America Mutual Fund and Milburn Country Club, where he was President. He also served for three years on the Public Policy and Education Committee of Kansas BIO.

Whitaker is a graduate of the Wharton School of Finance and Commerce at the University of Pennsylvania, where he earned a BS in economics. He received his law degree from the University of Missouri, Kansas City. In 2009 Whitaker was named an Ernst & Young “Entrepreneur of the Year” for the Central Midwest. Whitaker is a member of the Missouri Bar Association, Kansas City Bar Association and the Lawyers Association of Kansas City.

Howard M. Loree II, PhD

Vice President, Research and Development



With more than 18 years of increasing responsibility in medical device research and development, Howard M. Loree II, PhD, has a proven ability to recruit, lead, mentor and build exceptional engineering teams. He has a demonstrated hands-on aptitude across the entire product development life cycle, with emphasis on early-stage design and *in vivo* testing of rotary blood pump systems. Dr. Loree currently serves as Vice President of Research and Development at Flow Forward Medical, and also at Metactive Medical, a company developing novel, endovascular medical devices for the treatment of peripheral and neurovascular diseases.

Prior to joining Flow Forward, Dr. Loree worked in management and technical roles at Thoratec Corporation and Abiomed, Inc. He has also served as the Vice President of Research for Orthopeutics, LP, and Avedro, Inc., two early-stage companies focused on nonsurgical technology for intervertebral disc repair and vision correction.

Dr. Loree holds BS and MS degrees in mechanical engineering from MIT and a PhD in medical engineering from the Harvard-MIT Division of Health Sciences and Technology with specialization in physiology and fluid mechanics. He completed his post-doctoral training in cardiovascular biomechanics at the Brigham and Women’s Hospital and Harvard Medical School through an NIH NRSA fellowship. Dr. Loree has raised more than \$2.6 million in NIH funding for medical device development, primarily through the SBIR program, and has supported several successful FDA submissions. He has published 14 articles in peer-reviewed journals, co-authored three book chapters, and holds two patents in the area of biomedical engineering.

About Flow Forward Medical

Flow Forward is developing a novel approach to rapidly establish high-quality vascular access sites for hemodialysis. The Arteriovenous Fistula Eligibility (AFE) System™ is a small, temporary, external blood pump designed to stimulate flow-mediated dilation to make more patients eligible for an arteriovenous fistula (AVF), and increase success rates after surgery. Establishment of a reliable AVF reduces morbidity and mortality in hemodialysis patients, as well as the overall cost of care. For additional information, please visit www.flowforwardmedical.com.